TABLE 3

Maternal Vaccine Hesitancy: Results

Control, n (%)Intervention, n (%)ORa (P)Adjusted ORb (95% CI)
BaselineMonth 6BaselineMonth 6
Vaccine hesitant, %
 PACVc
  50–10025 (12.6)14 (8.0)19 (9.8)d13 (7.5)0.93 (.78)1.22e (0.47–2.68)f
Vaccine hesitant, ordinal
 PACVg
  0–29h140 (70.7)139 (79.9)144 (74.6)i138 (79.8)0.95 (.86)1.13 (0.61–2.10)j
  30–4933 (16.7)21 (12.1)30 (15.5)22 (12.7)
  50–5915 (7.6)6 (3.4)13 (6.7)8 (4.6)
  60–695 (2.5)4 (2.3)3 (1.6)2 (1.2)
  70+5 (2.5)4 (2.3)3 (1.6)3 (1.7)
  • a OR for difference in month 6 hesitancy between intervention and control groups.

  • b Adjusted for baseline PACV hesitancy score and race (2 indicator variables for white, Asian, and all other races).

  • c PACV, score 50–100. Estimated with GEE logistic regression with empirical SEs.

  • d OR for baseline difference between groups 0.76 (P = .43) (Table 1).

  • e OR >1.0 corresponds to a higher hesitancy rate in the intervention group.

  • f P = .71

  • g Proportional odds regression with mixed effects to account for within-clinic correlation. ORs estimate the odds of being at a higher hesitancy category.

  • h PACV, scores 0–100 where 100 is most hesitant; ≥50 indicates vaccine hesitancy.

  • i OR for baseline difference between groups: 0.78 (P = .42).

  • j P = .60.